Pfizer (PFE) And Medivation (MDVN) Initiate Two Phase 3 Trials Of Dimebon
More News related to MDVN
- Medivation to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
- Roth Capital Upgrades Medivation (MDVN) to Buy
- Medivation (MDVN) Reports Q3 Loss of $0.42, Misses by 3c
- Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
More News related to PFE
- Pfizer Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults
- FDA Approves Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
- Trading Review for Vivus Inc. Issued by Beacon Equity
- FDA Advisory Committee Finds Data Support the Claim That SPIRIVA(R) HandiHaler(R) Reduces COPD Exacerbations
- Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD).
The CONTACT study will assess as primary endpoints the potential benefits of adding dimebon to ongoing treatment with donepezil HCI tablets, the leading AD medication worldwide, on neuropsychiatric symptoms and activities of daily living. The CONSTELLATION study will evaluate as primary endpoints the effects of adding dimebon to memantine HCI, another standard of care, on cognition, memory and activities of daily living.
In preclinical studies, dimebon has been shown to protect brain cells from damage and enhance brain cell survival, potentially by stabilizing and improving mitochondrial function. The dimebon mechanism is distinct from currently available AD medications.
[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.59Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
